Veracyte | VCYT - Cash And Equivalent


Veracyte reported $263.14M in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
Agenus USD 35M 32M Mar/2026
Agilent USD 1.81B 49M Mar/2026
Anika Therapeutics USD 41.02M 16.46M Mar/2026
Arrowhead Research USD 201.64M 112.94M Dec/2025
Bruker USD 133.4M 165.4M Mar/2026
Heron Therapeutics USD 26.12M 2.53M Mar/2026
Illumina USD 1.42B 368M Dec/2025
Intrexon USD 9.34M 1.77M Jun/2024
Karyopharm Therapeutics USD 60.54M 22.87M Dec/2025
Laboratory Of America USD 981.1M 448.8M Mar/2026
Ligand Pharmaceuticals USD 115.08M 59.85M Mar/2026
Myriad Genetics USD 124.4M 25.2M Mar/2026
Rigel Pharmaceuticals USD 48.53M 4.87M Sep/2025
Roche Holding CHF 7.55B 579M Jun/2025
Sangamo BioSciences USD 38.34M 13.16M Jun/2025
Siemens EUR 15.26B 768M Dec/2025
Sonic Healthcare AUD 645M 25.39M Jun/2024
Thermo Fisher Scientific USD 3.25B 6.6B Mar/2026
Veracyte USD 263.14M 99.44M Mar/2026
Waters USD 462M 125.83M Mar/2026